Gregory L Moore

US Patent:

7610156, Oct 27, 2009

Filed:

Sep 30, 2004

Appl. No.:

10/956352

Inventors:

John R. Desjarlais - Pasadena CA, US
Jonathan Zalevsky - Riverside CA, US
Gregory L. Moore - Pasadena CA, US

Assignee:

Xencor, Inc. - Monrovia CA

International Classification:

G06F 19/00

US Classification:

702 27

Abstract:

The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.

US Patent:

8063187, Nov 22, 2011

Filed:

May 30, 2008

Appl. No.:

12/156183

Inventors:

Seung Yup Chu - Cypress CA, US
John R. Desjarlais - Pasadena CA, US
Sher Bahadur Karki - Pomona CA, US
Gregory Alan Lazar - Arcadia CA, US
Gregory L. Moore - Monrovia CA, US
Igor Vostiar - Monrovia CA, US

Assignee:

Xencor, Inc. - Monrovia CA

International Classification:

C07K 16/00
C12P 21/08
A61K 39/395
A61K 39/00
A61K 39/42
C07K 17/00

US Classification:

5303871, 5303873, 5303877, 5303881, 53038822, 5303887, 53038873, 4241301, 4241331, 4241411, 4241421, 4241431, 4241441, 4241521, 4241551, 4241721, 4241741

Abstract:

The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.

US Patent:

8314213, Nov 20, 2012

Filed:

Apr 20, 2009

Appl. No.:

12/426785

Inventors:

Matthew J. Bernett - Monrovia CA, US
Gregory Moore - Monrovia CA, US
John R. Desjarlais - Pasadena CA, US

Assignee:

Xencor, Inc. - Monrovia CA

International Classification:

C07K 16/28

US Classification:

5303882, 5303887

Abstract:

The present invention is directed to the creation of human equivalent CDRs and antibodies containing them by a method of producing an antibody which specifically binds to an antigen.

US Patent:

8362210, Jan 29, 2013

Filed:

Jan 19, 2011

Appl. No.:

13/009820

Inventors:

Gregory A. Lazar - Arcadia CA, US
Sher Bahadur Karki - Pomona CA, US
Gregory L. Moore - Monrovia CA, US

Assignee:

Xencor, Inc. - Monrovia CA

International Classification:

C07K 16/00
C12P 21/08
A61K 39/395
A61K 39/40
A61K 39/42
C07K 1/00

US Classification:

5303871, 5303873, 5303877, 5303881, 53038815, 53038822, 53038823, 4241301, 4241321, 4241331, 4241341, 4241411, 4241421, 4241431, 4241441, 4241451, 4241521, 4241531, 4241561, 4241581

Abstract:

The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e. g. , Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.

US Patent:

20050181994, Aug 18, 2005

Filed:

Oct 12, 2004

Appl. No.:

10/952493

Inventors:

Aaron Chamberlain - Pasadena CA, US
John Desjarlais - Pasadena CA, US
Gregory Moore - Pasadena CA, US

International Classification:

A61K038/17
C07K014/74

US Classification:

514012000, 530350000

Abstract:

The present invention relates to soluble, recombinant CD40L variant proteins that may be expressed solubly in . The variants of the present invention may substantially reduced binding to alpha IIb-beta3 integrin, act as CD40L antagonists or agonists, and methods for generating the same.

US Patent:

20060209705, Sep 21, 2006

Filed:

Mar 17, 2005

Appl. No.:

11/083434

Inventors:

Susan Sauter - Murphy TX, US
Jason Frazier - Raleigh NC, US
Ian Foo - Raleigh NC, US
Gregory Moore - Sedalia MO, US
Troy Sherman - San Jose CA, US

International Classification:

H04J 1/16
H04L 12/66

US Classification:

370252000, 370352000

Abstract:

According to one embodiment, a method for removing authentication of a supplicant includes monitoring communication between the supplicant and an authenticator. The method also includes determining, based on the monitored communication, the MAC address for the supplicant and an attachment port of the supplicant to the intermediate network device disposed between the supplicant and the authenticator through which the monitored communication occurs. The method also includes determining that the supplicant no longer has a link connection with the intermediate network device, and in response, sending via the intermediate network device a logoff message having a spoofed source address of the supplicant to the authenticator.

US Patent:

20060228758, Oct 12, 2006

Filed:

Mar 23, 2006

Appl. No.:

11/388570

Inventors:

Umesh Muchhal - Monrovia CA, US
John Desjarlais - Pasadena CA, US
Gregory Moore - Pasadena CA, US

International Classification:

G01N 33/53
G06F 19/00

US Classification:

435007100, 702019000

Abstract:

Methods, apparatuses, and compounds for screening or detecting binding of candidate peptides to an MHC protein is provided. A first component including at least one candidate peptides and a second component including at least one MHC protein are contacted. One of the components is immobilized on a solid support. The presence, absence, or quantity of binding of the peptide and said MHC protein is then determined.

US Patent:

20060228759, Oct 12, 2006

Filed:

Mar 23, 2006

Appl. No.:

11/388642

Inventors:

Umesh Muchhal - Monrovia CA, US
John Desjarlais - Pasadena CA, US
Gregory Moore - Pasadena CA, US

International Classification:

G01N 33/53
G06F 19/00

US Classification:

435007100, 702019000

Abstract:

Methods, apparatuses, and compounds for screening or detecting binding of candidate peptides to an MHC protein is provided. A first component including at least one candidate peptides and a second component including at least one MHC protein are contacted. One of the components is immobilized on a solid support. The presence, absence, or quantity of binding of the peptide and said MHC protein is then determined.